EAM
CASC

EverPoint Asset Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

EverPoint Asset Management’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-133,333
Closed -$1.31M – 590
2016
Q3 		$1.31M Sell
133,333
-116,667
-47% -$827K 0.02% 372
2016
Q2 		$1.42M Buy
+250,000
New +$1.7M 0.03% 340

Other funds holding CASC

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SH
Sandia Holdings Greenwich, Connecticut $213M AUM 29.35% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

EverPoint Asset Management's CASC Position: Q4 2016 in Review

EverPoint Asset Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q4 2016, closing a stake of 133,333 shares — an estimated $1.31M sold.

EverPoint Asset Management first reported a position in CASC in Q2 2016 and held it in 2 quarters. The position peaked at $1.42M in Q2 2016. 57 funds tracked by Wall St. Rank hold CASC as of Q4 2016.

  • EverPoint Asset Management reported no remaining Cascadian Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • EverPoint Asset Management sold 133,333 Cascadian Therapeutics, Inc. shares in Q4 2016, an estimated $1.31M.
  • EverPoint Asset Management first reported a position in Cascadian Therapeutics, Inc. in Q2 2016 and held it in 2 quarters.
  • EverPoint Asset Management's Cascadian Therapeutics, Inc. position peaked at $1.42M in Q2 2016.
  • 57 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.